New blood-thinning drug offers greater benefits
The findings of a recent worldwide trial show that the new anticoagulant drug apixaban was 21 percent more effective at preventing strokes in patients with atrial fibrilliation than warfarin (Coumadin), the current standard of care. The study, presented at the European Society of Cardiology in Paris and published in the New England Journal of Medicine, spanned nearly two years and included over 18,000 participants.
